New kind of print. Called reduction printing. You print later and then you carve it again. Each layer gets its own color. You make a series, but you can only do as many as the first layer, minus screw-ups. Behold King Gila MMXXIV Joel M. Topf, MD FACP Matthew Sparks, MD Cristina Popa

. #FLOW , one of the most highly anticipated #CKM trials of yr, to be presented #ERA24

Sema 1.0mg once weekly *disease modifying* in CKD+T2D
✅ ↓ Composite kidney events
✅ Slower eGFR decline
✅ ↓ MACE
✅ ↓ All-cause mortality

A new era, firmly establishes 4th pillar in #CKD !

Fascinating review.

Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
sciencedirect.com/science/articl…

The new powerful GLP-1 medicines at doses used for #obesity are relatively new. Yet the class of GLP-1 medicines is now 19 years old, with Exenatide approved for #T2D April 28 2005. We have millions of treatment years for this class. Happy birthday Exenatide/GLP-1 medicines!

Day at the Zoo Zoológicos CDMX and medicines were mentioned in passing… Gila The NephMadness Monster #NephMadness

Damn, this brought tears to my eyes #CKD #GDMT #flozinate #glipinate #pharmanuke bmj.com/content/385/bm…

Bringing up baby and first trimester exposure to GLP-1RA-no evidence for harm #pregnancy The BMJ bmjopen.bmj.com/content/14/4/e…. #T2D #obesity

Gila The NephMadness Monster AJKD A perfect 🦎🦎🦎🦎🦎🦎🦎🦎🦎🦎/10, no doubt about it

GLP-1 analogues that induce prolonged signaling relative to GLP-1 Patrick M Sexton biorxiv.org/content/10.110…

I like these tables. It's easier to decide when it's more appropriate to #Flozinate or to #glipinate
#NephMadness

acpjournals.org/doi/10.7326/M2…

#NephMadness 2024 went live on March 1st but planning started well before that. This initiative could not happen without the #NephTwitter community - we are immensely grateful to everyone who helped us develop the content as well as everyone who participated in the tournament!

Among patients with obesity-related heart failure with preserved ejection fraction & type 2 diabetes, semaglutide produced greater reductions in symptoms, physical limitations & body weight than placebo at 1 year. Full STEP-HFpEF DM trial results: nej.md/3TPKpUC

#ACC24

🎉Congrats to the winner of #NephMadness 2024 Best X Poster:

🏆Cristina Popa

'In the end, we are all winners, enriched by knowledge, stirred by emotion, and bound by memorable moments spent discussing nephrology and loving it!”

#NephMadness 2024: The Winners

buff.ly/3U0LdWQ